Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 3, 1998, Pages 397-401

  Klepser, Michael E ^a   Wolfe, Erika J ^a   Pfaller, Michael A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CRYPTOCOCCUS NEOFORMANS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY; TIME FACTORS;

EID: 0031946869     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.3.397     Document Type: Article

References (10)

1. Saag, M. S., Powderly, W. G., Cloud, G. A., Robinson, P., Grieco, M. H., Sharkey, P. K. et al. (1992). Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. New England Journal of Medicine 326,83-9.
2. van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D. etal. (1997). Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. New England Journal of Medicine 337,15-21.
3. Menichetti, F., Fiorio, M., Tosti, A., Gatti, F., Pasticci, M. B., Miletich, F. et al. (1996). High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 22,838-40.
4. Larsen, R. A., Leal, M. A. E. & Chan, L. S. (1990). Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Annals of Internal Medicine 113,183-7.
5. de Lalla, F., Pellizzer, G., Vaglia, A., Manfrin, V., Franzetti, M., Fabris, A. et al. (1995). Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clinical Infectious Diseases 20,263-6.
6. Dismukes, W. E., Cloud, G., Gallis, H. A., Kerkering, T. M., Medoff, G., Craven, P. C. et al. (1987). Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. New England Journal of Medicine 317,334-41.
7. National Committee for Clinical Laboratory Standards. (1995). Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts. Approved Standard M27-A. NCCLS, Villanova, PA.
8. Klepser, M. E., Wolfe, E. J., Jones, R. N., Nightingale, C. H. & Pfaller, M. A. (1997). Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Candida albicans. Antimicrobial Agents and Chemotherapy 41,1392-5.
9. Peasron, R. D., Steigbigel, R. T., Davis, H. T. & Chapman, S. W. (1980). Method for reliable determination of minimum lethal antibiotic concentrations. Antimicrobial Agents and Chemotherapy 18, 699-708.
10. Larsen, R. A., Bozzette, S. A., Jones, B. E., Haghighat, D., Leal, M. A., Forthal, D. et al. (1994). Fluconazole combined with flucytosine for the treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 19,741-5.